双环醇治疗慢性中度乙型病毒性肝炎疗效研究

目的观察双环醇(百赛诺,bicyclol)治疗慢性中度乙型病毒性肝炎的疗效。方法慢性中度乙型病毒性肝炎66例,随机分成两组,治疗组给予双环醇,对照组给予复方益肝灵,口服,疗程24周,停药后随访12周。观察临床症状、肝功能及乙型肝炎病毒(HBV)血清学标志。结果疗程结束后治疗组与对照组患者临床症状均有明显的改善;在降低丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)方面两组差异无显著性,而总胆红素(TBIL)的复常率治疗组高于对照组;治疗24周结束时双环醇组血清乙型肝炎病毒e抗原(HBeAg)、HBV-DNA阴转率(分别为33.3%和30.3%)和乙型肝炎病毒e抗体(HBeAb)阳转率(30.3%)明显高于对照组(分别为9.1%、6.1%和6.1%),而停药观察12周时差异无显著性。结论双环醇能明显改善慢性中度乙型病毒性肝炎患者的临床症状和肝功能,并且显示出一定的抗病毒作用。

An effect study on bicyclol treating chronic moderate hepatitis B

Objective To detect the efficacy of bicyclol on chronic hepatitis B. Methods Sixty-six patients suffered from chronic moderate hepatitis B were randomly divided into two groups. Thirty-three patients as treatment group received bicyclol and the other 33 patients as control group received co-yiganling for 24 weeks, then stopped treatment and followed up for 12 weeks. Investigating items included clinical symptoms, ALT, AST, BIL, serum hepatitis B virus (HBV) marks. Result After treatment, the clinical symptoms were relieved markedly, no adverse reactions occurred in two groups. The improvement of serum ALT and AST showed no significant statistical difference between the two groups, but the normalization rate of BIL in the bicyclol group was higher than that in the control; at the end of the 24th week the negative conversion rate of HBeAg, HBV-DNA, the positive conversion rate of HBeAb were 33.3%, 30.3% and 30.3% in the bicyclol group respectively, whereas those results in the control were 9.1%, 6.1% and 6.1% respectively. These results in the two groups showed statistic significance, but a 12 weeks observation after withdrawal showed no significant statistical difference between the two groups. Conclusion Bicyclol is a useful drug for alleviating the clinical symptoms and improving liver function, especially it exerts an efficient inhibition to the HBV replication. It shows good tolerance and safety throughout the course of treatment.